Premium
Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients
Author(s) -
Grimes Ronan T.,
Bennett Kathleen,
Tilson Lesley,
Usher Cara,
Smith Susan M.,
Henman Martin C.
Publication year - 2015
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12573
Subject(s) - medicine , regimen , persistence (discontinuity) , hazard ratio , proportional hazards model , cohort , population , cohort study , retrospective cohort study , pharmacy , diabetes mellitus , endocrinology , confidence interval , geotechnical engineering , environmental health , family medicine , engineering
Aims The aim was to describe the utilization of antidiabetic agents, in terms of persistence and regimen change, in the management of a cohort of newly treated type 2 diabetes patients and to investigate associated socio‐demographic and treatment factors. Methods A population‐based retrospective cohort study was conducted using the national pharmacy claims database in I reland. Subjects were analyzed for persistence and regimen change. Cox proportional hazards regression examined associations of socio‐demographic and treatment factors on treatment patterns. Hazard ratios ( HR ) and 95% CIs are presented. Results A total of 20947 subjects were identified in the study over a 2 year period. Most were initiated on metformin (76%) or sulphonylureas (22%) and 77% were persistent with therapy 12 months after initiation. The likelihood of non‐persistence was significantly lower in the youngest (40–49 years) age groups (reference 60–69 years) ( HR 1.62, 95% CI 1.42, 1.84) and those on sulphonylureas ( HR 1.49, 95% CI 1.36, 1.64). The likelihood of receiving a regimen change was significantly lower in the older (80+ years) age groups ( HR 0.63, 95% CI 0.56, 0.71), females ( HR 0.91, 95% CI 0.86, 0.95), and those with pre‐existing CVD (1 vs . 0 CVD medicines) ( HR 0.82, 95% CI 0.74, 0.90), and higher in those on sulphonylureas ( HR 1.83, 95% CI 1.73, 1.94). Conclusions Type of treatment, pre‐existing CVD and demographic factors are shown to be associated with the observed treatment patterns. Guideline recommended agents were widely used on treatment initiation though a substantial minority were not initiated on the recommended first line agent. Use of guideline recommended agents was not as evident during treatment progression. Further optimization of initial and subsequent antidiabetic agent prescribing may be possible.